{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:23:41Z","timestamp":1790839421068,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bmcl.2022.129050","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T02:18:22Z","timestamp":1667873902000},"page":"129050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Lead identification of novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent heparanase-1 inhibitor"],"prefix":"10.1016","volume":"79","author":[{"given":"Yudai","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Wakasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Sugisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroh","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teisuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kakinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.129050_b0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbrc.2013.11.079","article-title":"1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase","volume":"443","author":"Wilson","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmcl.2022.129050_b0010","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nsmb.3136","article-title":"Structural characterization of human heparanase reveals insights into substrate recognition","volume":"22","author":"Liang","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmcl.2022.129050_b0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.ki.5002337","article-title":"Heparanase in glomerular diseases","volume":"72","author":"van den Hoven","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.bmcl.2022.129050_b0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ndt\/gft410","article-title":"The role of heparanase and the endothelial glycocalyx in the development of proteinuria","volume":"29","author":"Garsen","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bmcl.2022.129050_b0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ajpath.2015.12.008","article-title":"Heparanase is essential for the development of acute experimental glomerulonephritis","volume":"186","author":"Garsen","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bmcl.2022.129050_b0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/01.ASN.0000103229.25389.40","article-title":"Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis","volume":"15","author":"Levidiotis","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bmcl.2022.129050_b0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1797.2005.00388.x","article-title":"Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease","volume":"10","author":"Levidiotis","year":"2005","journal-title":"Nephrology (Carlton)."},{"key":"10.1016\/j.bmcl.2022.129050_b0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2337\/db11-1024","article-title":"Heparanase is essential for the development of diabetic nephropathy in mice","volume":"61","author":"Gil","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.bmcl.2022.129050_b0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.fob.2013.07.007","article-title":"Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues","volume":"3","author":"Hammond","year":"2013","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bmcl.2022.129050_b0050","first-page":"1071","article-title":"Roneparstat and heparanase inhibition: a new tool for cancer treatment","volume":"5","author":"Barbieri","year":"2017","journal-title":"J Pharmacol Clin Toxicol."},{"key":"10.1016\/j.bmcl.2022.129050_b0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bmcl.2005.09.069","article-title":"1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors","volume":"16","author":"Pan","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.129050_b0060","doi-asserted-by":"crossref","first-page":"e82111","DOI":"10.1371\/journal.pone.0082111","article-title":"Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site","volume":"8","author":"Vinader","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2022.129050_b0065","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7164\/antibiotics.47.101","article-title":"Totally synthetic analogs of siastatin B. III. Trifluoroacetamide analogs having inhibitory activity for tumor metastasis","volume":"47","author":"Nishimura","year":"1994","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmcl.2022.129050_b0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7164\/antibiotics.53.211","article-title":"CRM646-A and -B, novel fungal metabolites that inhibit heparinase","volume":"53","author":"Ko","year":"2000","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmcl.2022.129050_b0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7164\/antibiotics.37.187","article-title":"Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-Methyl erythromycins A","volume":"37","author":"Morimoto","year":"1984","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmcl.2022.129050_b0080","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","article-title":"(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment","volume":"53","author":"Kakinuma","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.129050_b0085","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/jo051384k","article-title":"Total synthesis of CRM646-A and -B, two fungal glucuronides with potent heparinase inhibition activities","volume":"70","author":"Wang","year":"2005","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmcl.2022.129050_b0090","unstructured":"Assay of HPSE1 inhibition: the human HPSE1 inhibition studies were performed using HTRF technology (Cisbio). Recombinant human HPSE1 was diluted to 8 ng\/mL with an enzyme buffer (20 mM Tris-HCl, 150 mM NaCl, 0.02% bovine serum albumin, 0.02% Pluronic F-127, pH7.5). Various concentrations of compounds (0.2 \u03bcL in DMSO) were added to 10 \u03bcL of the enzyme solutions, and the solutions were incubated for 10 min at room temperature. Then, 10 \u03bcL of biotin-heparan sulfate-Eu cryptate (0.8 \u03bcg\/mL in 40 mM of acetate buffer, pH5.2) was added to the solution. After 60 min of incubation at 21\u00b0C, 20 \u03bcL of stop solution (0.625 \u03bcg\/mL Streptavidin-d2, 0.8 M potassium fluoride, 2 mg\/mL heparin, 0.1 M phosphate buffer, pH8.0) was added to the reaction mixture and the mixture was incubated for 15 min. Then, the fluorescence (665 nm and 615 nm) was measured using ARVO (PerkinElmer Japan Co., Ltd.). The fluorescence ratio for 665 nm over 615 nm was then used to calculate the IC50 values."},{"key":"10.1016\/j.bmcl.2022.129050_b0095","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1016\/j.tet.2006.08.055","article-title":"\u03b1- and \u03b2-Glucosidase inhibitors: chemical structure and biological activity","volume":"62","author":"de Melo","year":"2006","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2022.129050_b0100","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.7164\/antibiotics.45.1404","article-title":"Nagstatin, a new inhibitor of N-acetyl-\u03b2-D-glucosaminidase, produced by Streptomyces amakusaensis MG846-fF3. Taxonomy, production, isolation, physico-chemical properties and biological activities","volume":"45","author":"Aoyagi","year":"1992","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmcl.2022.129050_b0105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.7164\/antibiotics.48.286","article-title":"Syntheses and glycosidase inhibiting activities of nagstatin analogs","volume":"48","author":"Tatsuta","year":"1995","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmcl.2022.129050_b0110","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hlca.200690137","article-title":"Synthesis of glucuronic, mannuronic, and galacturonic acid-derived imidazoles as inhibitors of bovine liver \u03b2-glucuronidase","volume":"89","author":"Pabba","year":"2006","journal-title":"Helv Chim Acta"},{"key":"10.1016\/j.bmcl.2022.129050_b0115","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/oxfordjournals.jbchem.a130677","article-title":"beta-Glucuronidase of bovine liver. Purification, properties, carbohydrate composition","volume":"76","author":"Himeno","year":"1974","journal-title":"J Biochem"},{"key":"10.1016\/j.bmcl.2022.129050_b0120","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/S0021-9258(19)39371-8","article-title":"A new type of exo-beta-glucuronidase acting only on non-sulfated glycosaminoglycans","volume":"265","author":"Nakamura","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.129050_b0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI72339","article-title":"Lysosomal \u03b2-glucuronidase regulates Lyme and rheumatoid arthritis severity","volume":"124","author":"Bramwell","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmcl.2022.129050_b0130","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bmc.2011.02.043","article-title":"Structure\u2013activity relationships in a series of C2-substituted gluco-configured tetrahydroimidazopyridines as \u03b2-glucosidase inhibitors","volume":"19","author":"Li","year":"2011","journal-title":"Bioorg Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22005261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22005261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:16Z","timestamp":1760773576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22005261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":26,"alternative-id":["S0960894X22005261"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.129050","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lead identification of novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent heparanase-1 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.129050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129050"}}